Sarepta Therapeutics, Inc.
EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
Last updated:
Abstract:
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
Status:
Application
Type:
Utility
Filling date:
11 Oct 2021
Issue date:
18 Aug 2022